CashNews.co
The UK stock market has recently faced challenges, with the FTSE 100 and FTSE 250 indices slipping due to weak trade data from China, highlighting the interconnectedness of global economies. Despite these broader market pressures, there remains interest in exploring investment opportunities beyond the major players. Penny stocks, while an older term, continue to capture attention for their potential value and growth prospects when backed by strong financials.
Name |
Share Price |
Market Cap |
Financial Health Rating |
FRP Advisory Group (AIM:FRP) |
£1.47 |
£347M |
★★★★★★ |
ME Group International (LSE:MEGP) |
£2.18 |
£840.18M |
★★★★★★ |
Polar Capital Holdings (AIM:POLR) |
£4.895 |
£476.63M |
★★★★★★ |
Next 15 Group (AIM:NFG) |
£3.94 |
£397.82M |
★★★★☆☆ |
Supreme (AIM:SUP) |
£1.55 |
£191.24M |
★★★★★★ |
Tristel (AIM:TSTL) |
£4.20 |
£193.46M |
★★★★★★ |
Stelrad Group (LSE:SRAD) |
£1.50 |
£188.48M |
★★★★★☆ |
Luceco (LSE:LUCE) |
£1.334 |
£208.83M |
★★★★★☆ |
Impax Asset Management Group (AIM:IPX) |
£3.53 |
£445.31M |
★★★★★★ |
Serabi Gold (AIM:SRB) |
£0.91 |
£70.81M |
★★★★★★ |
Click here to see the full list of 472 stocks from our UK Penny Stocks screener.
We’ll examine a selection from our screener results.
Simply Wall St Financial Health Rating: ★★★★★★
Overview: Poolbeg Pharma PLC is a biopharmaceutical company focused on developing and commercializing medicines for unmet medical needs in the United Kingdom, with a market cap of £44 million.
Operations: Poolbeg Pharma PLC has not reported any specific revenue segments.
Market Cap: £44m
Poolbeg Pharma is a pre-revenue biopharmaceutical company with a market cap of £44 million, making it a potential candidate for penny stock investors. The company recently reported an increased net loss of £2.26 million for the first half of 2024, highlighting its current unprofitable status. Despite having no debt and sufficient short-term assets to cover liabilities, Poolbeg’s earnings are forecasted to decline over the next three years. The management team is relatively new with less than one year average tenure, contributing to its high share price volatility and negative return on equity at -35.17%.
Simply Wall St Financial Health Rating: ★★★★☆☆
Overview: Genel Energy plc is an independent oil and gas exploration and production company with a market capitalization of £216.20 million.
Operations: The company generates revenue from its production segment, amounting to $74.4 million.